<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672204</url>
  </required_header>
  <id_info>
    <org_study_id>0612M98726</org_study_id>
    <nct_id>NCT00672204</nct_id>
  </id_info>
  <brief_title>Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes</brief_title>
  <acronym>RAPTIVA</acronym>
  <official_title>Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this protocol is to test the safety and efficacy of a treatment&#xD;
      regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed&#xD;
      by withdrawal of efalizumab and maintenance therapy with sirolimus, for the prevention of the&#xD;
      destruction and rejection of islet transplants in type 1 diabetic recipients.&#xD;
&#xD;
      Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market&#xD;
      in April of 2009. Previously transplanted subjects have been transitioned to alternative&#xD;
      immunosuppressives and no new subjects will be transplanted under this protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to improve the applicability of islet transplantation for&#xD;
      treatment of type 1 diabetes utilizing a novel immunosuppressive regimen centered on the use&#xD;
      of adhesion molecule blockade with an anti-LFA-1 antibody (efalizumab). The&#xD;
      lymphocyte-function associated antigen-1 (LFA-1) adhesion molecule is expressed on multiple&#xD;
      cellular populations including T cells, B cells, and NK cells and is important in&#xD;
      facilitating cell migration and homing. In addition, interaction of LFA-1 with its ligand&#xD;
      ICAM-1 on antigen presenting cells provides a powerful costimulatory signal for T cell&#xD;
      activation.&#xD;
&#xD;
      Animal models using anti-LFA-1 antibodies have shown impressive prolongation of vascularized&#xD;
      and cellular allograft survival. These potent immunosuppressive properties have also been&#xD;
      documented in several clinical trials with efalizumab, a humanized IgG1 monoclonal antibody&#xD;
      directed against LFA-1. The drug was found to be safe, well tolerated, and efficacious in&#xD;
      treating moderate to severe psoriasis.&#xD;
&#xD;
      More recently, a multicenter trial employing efalizumab in conjunction with prednisone,&#xD;
      sirolimus and cyclosporine maintenance immunosuppression in recipients of kidney allografts&#xD;
      showed an acceptable safety profile when used at a dose of 0.5mg/kg/week and excellent&#xD;
      rejection-free graft survival over the first 6 months after transplant.&#xD;
&#xD;
      This study represents the first clinical trial that applies adhesion molecule blockade with&#xD;
      efalizumab to prevent the immune response against pancreatic islets in the setting of type 1&#xD;
      diabetes mellitus, with the long-term goal of immunosuppression withdrawal.&#xD;
&#xD;
      Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market&#xD;
      in April of 2009. Previously transplanted subjects have been transitioned to alternative&#xD;
      immunosuppressives and no new subjects will be transplanted under this protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Raptiva was withdrawn from the market&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Insulin-independent Subjects With Full Islet Graft Function</measure>
    <time_frame>1 year following the first islet transplant</time_frame>
    <description>Islet transplant recipients will be considered insulin-independent with full islet graft function if they are able to titrate off insulin therapy for at least 1 week and all of the following criteria are met:&#xD;
HbA1c &lt; 7.0% or a ≥2.5% decrease from baseline;&#xD;
fasting capillary glucose level should not exceed 140 mg/dL (7.8 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 7 times in a seven day period);&#xD;
2-hour post-prandial capillary glucose should not exceed 180 mg/dl (10.0 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 21 times in a seven day period);&#xD;
fasting serum glucose level ≤126 mg/dL (7.0 mmol/L); if the fasting serum glucose level is &gt;126 mg/dL (7.0 mmol/L), it must be confirmed in an additional one out of two measurements;&#xD;
evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥0.5 ng/mL (0.16 nmol/L).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic islets of Langerhans</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic islets of Langerhans transplant</intervention_name>
    <description>Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Islets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
    <description>Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Efalizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>2.0 mg/kg on days -2, and -1 IV</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary islet allotransplant&#xD;
&#xD;
          2. Type I diabetes mellitus for a minimum of 5 years&#xD;
&#xD;
          3. One of the following signs or symptoms despite intensive efforts made in close&#xD;
             cooperation with their diabetic care team:&#xD;
&#xD;
               -  Metabolic lability/instability characterized by hypoglycemia or ketoacidosis (&gt;2&#xD;
                  hospital admissions in the previous year), erratic glucose profiles (MAGE&gt;120&#xD;
                  mg/dL), or disruption in lifestyle of danger to life, self or others&#xD;
&#xD;
               -  Reduced awareness of hypoglycemia or &gt;1 episode in the last 1.5 years of severe&#xD;
                  hypoglycemia&#xD;
&#xD;
               -  Persistently poor glucose control (as defined by HgbA1c&gt;10% at the end of six&#xD;
                  months of intensive management efforts with the diabetes care team)&#xD;
&#xD;
               -  Progressive secondary complications as defined by (i) a new diagnosis by an&#xD;
                  ophthalmologist of proliferative retinopathy or clinically significant macular&#xD;
                  edema or therapy with photocoagulation during the last year; or (ii) urinary&#xD;
                  albumin excretion rate &gt;300 mg/day but proteinuria &lt;3g/day; or (iii) symptomatic&#xD;
                  autonomic neuropathy (as defined by postural hypotension in the setting of&#xD;
                  euvolemia, gastroparesis or diarrhea attributed to diabetic neuropathy, or&#xD;
                  neuropathic bladder as diagnosed by an urologist)&#xD;
&#xD;
          4. Age 18 to 65 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use of immunosuppressive agents&#xD;
&#xD;
          2. Lymphopenia (&lt;1000/µL) or leukopenia (&lt;3000 total leukocytes/µL)&#xD;
&#xD;
          3. Presence of panel-reactive anti-HLA antibody &gt;20%&#xD;
&#xD;
          4. Positive lymphocytotoxic cross-match using donor lymphocytes and serum&#xD;
&#xD;
          5. Evidence of acute EBV infection (IgM&gt;IgG) OR negative screen for EBV by IgG&#xD;
             determination&#xD;
&#xD;
          6. Calculated or measured GFR &lt; 60 ml/min/m2&#xD;
&#xD;
          7. Portal hypertension or history of significant liver disease&#xD;
&#xD;
          8. History of malignancy within 10 years (except for adequately treated basal or squamous&#xD;
             cell CA of the skin)&#xD;
&#xD;
          9. Active peptic ulcer disease&#xD;
&#xD;
         10. Severe unremitting diarrhea or other GI disorders potentially interfering with the&#xD;
             ability to absorb oral medications&#xD;
&#xD;
         11. Untreated proliferative retinopathy&#xD;
&#xD;
         12. Pregnancy or breastfeeding&#xD;
&#xD;
         13. Female subjects not post-menopausal or surgically sterile, or not using an acceptable&#xD;
             method of contraception&#xD;
&#xD;
         14. Active infections&#xD;
&#xD;
         15. Serologic evidence of infection with HIV, or HbsAg or HCV Ab positive&#xD;
&#xD;
         16. Major ongoing psychiatric illness&#xD;
&#xD;
         17. Ongoing substance abuse, drug or alcohol; or recent history of noncompliance&#xD;
&#xD;
         18. Any condition that in the opinion of the Principle Investigator would not allow for&#xD;
             safe participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard J. Hering, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universtiy of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.surg.umn.edu/diabinst/home.html</url>
    <description>U of MN Diabetes Institute for Immunology and Transplantation</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>February 20, 2013</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2013</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet transplant</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from 2008 - 2009 at the University of Minnesota.</recruitment_details>
      <pre_assignment_details>Raptiva was removed from market.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic Islets of Langerhans</title>
          <description>Allogeneic islets of Langerhans&#xD;
anti-thymocyte globulin : 2.0 mg/kg on days -2, and -1 IV&#xD;
Raptiva : Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;&#xD;
Allogeneic islets of Langerhans transplant : Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.&#xD;
Sirolimus : Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic Islets of Langerhans</title>
          <description>Allogeneic islets of Langerhans&#xD;
anti-thymocyte globulin : 2.0 mg/kg on days -2, and -1 IV&#xD;
Raptiva : Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;&#xD;
Allogeneic islets of Langerhans transplant : Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.&#xD;
Sirolimus : Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Insulin-independent Subjects With Full Islet Graft Function</title>
        <description>Islet transplant recipients will be considered insulin-independent with full islet graft function if they are able to titrate off insulin therapy for at least 1 week and all of the following criteria are met:&#xD;
HbA1c &lt; 7.0% or a ≥2.5% decrease from baseline;&#xD;
fasting capillary glucose level should not exceed 140 mg/dL (7.8 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 7 times in a seven day period);&#xD;
2-hour post-prandial capillary glucose should not exceed 180 mg/dl (10.0 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 21 times in a seven day period);&#xD;
fasting serum glucose level ≤126 mg/dL (7.0 mmol/L); if the fasting serum glucose level is &gt;126 mg/dL (7.0 mmol/L), it must be confirmed in an additional one out of two measurements;&#xD;
evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥0.5 ng/mL (0.16 nmol/L).</description>
        <time_frame>1 year following the first islet transplant</time_frame>
        <population>Raptiva was removed from market after 3 subjects were transplanted</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Islets of Langerhans</title>
            <description>Allogeneic islets of Langerhans&#xD;
anti-thymocyte globulin : 2.0 mg/kg on days -2, and -1 IV&#xD;
Raptiva : Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;&#xD;
Allogeneic islets of Langerhans transplant : Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.&#xD;
Sirolimus : Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Insulin-independent Subjects With Full Islet Graft Function</title>
          <description>Islet transplant recipients will be considered insulin-independent with full islet graft function if they are able to titrate off insulin therapy for at least 1 week and all of the following criteria are met:&#xD;
HbA1c &lt; 7.0% or a ≥2.5% decrease from baseline;&#xD;
fasting capillary glucose level should not exceed 140 mg/dL (7.8 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 7 times in a seven day period);&#xD;
2-hour post-prandial capillary glucose should not exceed 180 mg/dl (10.0 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 21 times in a seven day period);&#xD;
fasting serum glucose level ≤126 mg/dL (7.0 mmol/L); if the fasting serum glucose level is &gt;126 mg/dL (7.0 mmol/L), it must be confirmed in an additional one out of two measurements;&#xD;
evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥0.5 ng/mL (0.16 nmol/L).</description>
          <population>Raptiva was removed from market after 3 subjects were transplanted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic Islets of Langerhans</title>
          <description>Allogeneic islets of Langerhans&#xD;
anti-thymocyte globulin : 2.0 mg/kg on days -2, and -1 IV&#xD;
Raptiva : Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;&#xD;
Allogeneic islets of Langerhans transplant : Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.&#xD;
Sirolimus : Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to Raptiva being withdrawn from market</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bernhard J. Hering, M.D.</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-5735</phone>
      <email>bhering@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

